CDNA vs. SERA, CSTL, FLGT, GTH, BDSX, BNR, PSNL, VRDN, VCYT, and PEPG
Should you be buying CareDx stock or one of its competitors? The main competitors of CareDx include Sera Prognostics (SERA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Genetron (GTH), Biodesix (BDSX), Burning Rock Biotech (BNR), Personalis (PSNL), Viridian Therapeutics (VRDN), Veracyte (VCYT), and PepGen (PEPG).
CareDx (NASDAQ:CDNA) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.
54.6% of Sera Prognostics shares are owned by institutional investors. 4.2% of CareDx shares are owned by company insiders. Comparatively, 15.6% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, CareDx had 2 more articles in the media than Sera Prognostics. MarketBeat recorded 2 mentions for CareDx and 0 mentions for Sera Prognostics. CareDx's average media sentiment score of 1.57 beat Sera Prognostics' score of 0.00 indicating that CareDx is being referred to more favorably in the media.
CareDx currently has a consensus target price of $13.50, indicating a potential upside of 78.57%. Sera Prognostics has a consensus target price of $2.75, indicating a potential downside of 74.42%. Given CareDx's higher possible upside, equities analysts clearly believe CareDx is more favorable than Sera Prognostics.
CareDx has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.
CareDx has a net margin of -67.88% compared to Sera Prognostics' net margin of -11,843.79%. Sera Prognostics' return on equity of -45.74% beat CareDx's return on equity.
Sera Prognostics has lower revenue, but higher earnings than CareDx. Sera Prognostics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
CareDx received 413 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 66.56% of users gave CareDx an outperform vote while only 36.00% of users gave Sera Prognostics an outperform vote.
Summary
CareDx beats Sera Prognostics on 9 of the 17 factors compared between the two stocks.
Get CareDx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
